Similar Outcomes for IPF Patients Found for Esbriet, Ofev in Analysis

Similar Outcomes for IPF Patients Found for Esbriet, Ofev in Analysis

311219

Similar Outcomes for IPF Patients Found for Esbriet, Ofev in Analysis

People with idiopathic pulmonary fibrosis (IPF) had the same mortality and hospitalization rates, and incurred similar healthcare costs, whether they were treated with Esbriet (pirfenidone) or Ofev (nintedanib), a German insurance claims analysis showed. However, the analysis — conducted over five years and involving more than 1,000 patients — did not examine outcomes such as quality of life, lung function, and the side effects of the two IPF medications. Thus, the researchers said, the decision…

You must be logged in to read/download the full post.